PTSD News

A cognitive model of PTSD best predicted PTSD, complex PTSD, depression and anxiety among youth who experienced a single-event trauma, according to research published in Psychological Medicine.

Individuals exposed to conversion practice to alter sexual orientation or gender identity have significantly higher risk for developing symptoms of multiple mental health conditions, study results published in Lancet Psychiatry showed.

Aspects of PTSD across several dimensions were associated with menopause-related health in midlife women veterans such as urinary and vasomotor symptoms, vasomotor symptom interference and sexual dysfunction, researchers reported.

The COVID-19 pandemic had a great impact on the health care system and the well-being of health care professionals, the effects of which are still felt today.

There are two FDA-approved medications for PTSD, both selective serotonin reuptake inhibitors. The FDA has not approved a new medication for PTSD since 2001.

Individuals with type 2 diabetes who experience trauma may be at a lower risk for microvascular complications after resolving PTSD symptoms, according to a results from a retrospective study of U.S. veterans published in JAMA Network Open.

The Healio news staff received an APEX award in the category of Writing/Topics for work on the potential role of psychedelics and alternative therapies for mental health issues and other medical conditions.

The FDA on Aug. 9 issued a complete response letter to Lycos Therapeutics for its new drug application regarding midomafetamine capsules for the treatment of PTSD, citing insufficient data to approve and requesting an additional phase 3 trial.

NEW YORK — In this Healio Video Perspective, Reid Robison, MD, MBA, senior principal investigator at Numinus, a company that conducts clinical trials in psychedelics, discusses promising new treatment options for psychiatric conditions.